<DOC>
	<DOCNO>NCT00006015</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Monoclonal antibody trastuzumab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : This phase II trial study combination chemotherapy plus trastuzumab see well work treat patient advance , recurrent , metastatic colorectal cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Trastuzumab Treating Patients With Advanced , Recurrent , Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient overexpress HER-2/neu metastatic colorectal adenocarcinoma progress least 1 prior , 2 prior , chemotherapy regimen metastatic colorectal cancer treat fluorouracil , leucovorin calcium , oxaliplatin , trastuzumab ( Herceptin ) . - Determine time progression patient treat regimen . - Determine overall toxicity regimen patient . OUTLINE : Patients receive trastuzumab ( Herceptin ) IV 30-90 minute day 1 , 8 , 15 , 22 , follow oxaliplatin IV 2 hour day 1 15 , follow leucovorin calcium IV 2 hour day 1 , 8 , 15 . Fluorouracil IV administer midpoint leucovorin calcium infusion day 1 , 8 , 15 . Treatment continue every 28 day absence unacceptable toxicity disease progression . PROJECTED ACCRUAL : A total 20-45 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced , recurrent , metastatic colorectal adenocarcinoma Resected CNS metastases stable great 1 month completion radiotherapy CNS metastases eligible No exist CNS metastasis allow Measurable disease At least 1 dimension least 20 mm conventional technique OR At least 10 mm spiral CT scan No truly nonmeasurable lesion : Bone lesion Leptomeningeal disease Lymphangitis cutis/pulmonis Abdominal mass confirm followed imaging technique Cystic lesion Must progress least 1 prior , 2 prior , fluorouracil and/or irinotecan contain treatment regimen metastatic colorectal cancer Must document HER2/neu overexpression immunohistochemistry stain Staining score least 2+ PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2.0 mg/dL AST great 2.5 time upper limit normal Renal : Creatinine normal OR Creatinine clearance least 60 mL/min Cardiovascular : No history cardiac ischemia congestive heart failure LVEF least 50 % ECG MUGA Other : Not pregnant nursing Fertile patient must use effective contraception No concurrent second malignancy except nonmelanoma skin cancer carcinoma situ cervix unless complete therapy consider less 30 % risk relapse PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No prior platinum contain chemotherapy At least 3 week since prior chemotherapy recover No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 3 week since prior radiotherapy recover Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>